GLP-1 Discontinuation: What Happens When You Stop Taking the Medication

GLP-1 medications work while you take them. The research on what happens after stopping is clear — and patients planning around regulatory changes need to understand it.

The STEP 1 Extension Data

The STEP 1 trial extension followed participants who stopped semaglutide after 68 weeks of treatment. By one year after discontinuation:¹

• Participants had regained approximately two-thirds of their lost weight
• Cardiometabolic improvements (blood pressure, cholesterol) partially reversed
• Appetite suppression diminished within weeks of stopping

This isn't unique to semaglutide — it reflects the biological reality that obesity is a chronic condition. The brain's appetite regulation system resets when the medication is removed.

Why This Matters for Regulatory Changes

Patients considering stopping treatment due to regulatory uncertainty around compounding should understand: interrupting GLP-1 therapy typically leads to weight regain. Planning a transition to an alternative provider or formulation is strongly preferable to stopping treatment entirely.

Transition Strategies

• Switch formulations: Compounded injectable → oral Wegovy ($149/month, FDA-approved)
• Switch providers: 503B-dependent provider → 503A-partnered provider
• Explore insurance: Brand-name options may be covered; savings programs available
• Maintain without medication: If stopping is unavoidable, high protein intake, resistance training, and structured eating patterns can slow regain

The Source Summary

Stopping GLP-1 medication leads to significant weight regain in most patients — approximately two-thirds of lost weight returns within a year. This is a biological reality, not a personal failure. If regulatory changes threaten your current access, transition to an alternative rather than stopping treatment.